The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Therapies and Diagnostics for Ovarian Cancer Market Research Report 2025
Synopsis
Ovarian cancer (ovarian cancer) accounts for 2.4% ~ 6.5% of the common malignant tumors in women, and ranks the third among the cancers of the female reproductive system, secondary to cervical cancer and uterine body cancer.In recent years, due to the prevention and treatment of cervical cancer and uterine body cancer, some achievements have been made, while the prevention and treatment of ovarian cancer is relatively small.So ovarian cancer is the leading cause of death among cancers of the reproductive system in women.
The global Therapies and Diagnostics for Ovarian Cancer market was valued at US$ 1997.1 million in 2023 and is anticipated to reach US$ 2713.5 million by 2030, witnessing a CAGR of 4.0% during the forecast period 2024-2030.
North American market for Therapies and Diagnostics for Ovarian Cancer is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Therapies and Diagnostics for Ovarian Cancer is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Therapies and Diagnostics for Ovarian Cancer in Hospitals is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Therapies and Diagnostics for Ovarian Cancer include Astra Zeneca, Clovis Oncology, Myriad, TESARO, AbbVie Inc, Celgene, Janssen Pharmaceuticals, Merck and Novartis AG, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Therapies and Diagnostics for Ovarian Cancer, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Therapies and Diagnostics for Ovarian Cancer.
Report Scope
The Therapies and Diagnostics for Ovarian Cancer market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Therapies and Diagnostics for Ovarian Cancer market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Therapies and Diagnostics for Ovarian Cancer companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Astra Zeneca
Clovis Oncology
Myriad
TESARO
AbbVie Inc
Celgene
Janssen Pharmaceuticals
Merck
Novartis AG
Quest Diagnostics Inc
Segment by Type
Surgery
Radiation Therapy
Drug Treatment
Segment by Application
Hospitals
Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Therapies and Diagnostics for Ovarian Cancer companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Ovarian cancer (ovarian cancer) accounts for 2.4% ~ 6.5% of the common malignant tumors in women, and ranks the third among the cancers of the female reproductive system, secondary to cervical cancer and uterine body cancer.In recent years, due to the prevention and treatment of cervical cancer and uterine body cancer, some achievements have been made, while the prevention and treatment of ovarian cancer is relatively small.So ovarian cancer is the leading cause of death among cancers of the reproductive system in women.
The global Therapies and Diagnostics for Ovarian Cancer market was valued at US$ 1997.1 million in 2023 and is anticipated to reach US$ 2713.5 million by 2030, witnessing a CAGR of 4.0% during the forecast period 2024-2030.
North American market for Therapies and Diagnostics for Ovarian Cancer is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Therapies and Diagnostics for Ovarian Cancer is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Therapies and Diagnostics for Ovarian Cancer in Hospitals is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Therapies and Diagnostics for Ovarian Cancer include Astra Zeneca, Clovis Oncology, Myriad, TESARO, AbbVie Inc, Celgene, Janssen Pharmaceuticals, Merck and Novartis AG, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Therapies and Diagnostics for Ovarian Cancer, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Therapies and Diagnostics for Ovarian Cancer.
Report Scope
The Therapies and Diagnostics for Ovarian Cancer market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Therapies and Diagnostics for Ovarian Cancer market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Therapies and Diagnostics for Ovarian Cancer companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Astra Zeneca
Clovis Oncology
Myriad
TESARO
AbbVie Inc
Celgene
Janssen Pharmaceuticals
Merck
Novartis AG
Quest Diagnostics Inc
Segment by Type
Surgery
Radiation Therapy
Drug Treatment
Segment by Application
Hospitals
Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Therapies and Diagnostics for Ovarian Cancer companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Therapies and Diagnostics for Ovarian Cancer Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Surgery
1.2.3 Radiation Therapy
1.2.4 Drug Treatment
1.3 Market by Application
1.3.1 Global Therapies and Diagnostics for Ovarian Cancer Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Therapies and Diagnostics for Ovarian Cancer Market Perspective (2019-2030)
2.2 Therapies and Diagnostics for Ovarian Cancer Growth Trends by Region
2.2.1 Global Therapies and Diagnostics for Ovarian Cancer Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Therapies and Diagnostics for Ovarian Cancer Historic Market Size by Region (2019-2024)
2.2.3 Therapies and Diagnostics for Ovarian Cancer Forecasted Market Size by Region (2025-2030)
2.3 Therapies and Diagnostics for Ovarian Cancer Market Dynamics
2.3.1 Therapies and Diagnostics for Ovarian Cancer Industry Trends
2.3.2 Therapies and Diagnostics for Ovarian Cancer Market Drivers
2.3.3 Therapies and Diagnostics for Ovarian Cancer Market Challenges
2.3.4 Therapies and Diagnostics for Ovarian Cancer Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Therapies and Diagnostics for Ovarian Cancer Players by Revenue
3.1.1 Global Top Therapies and Diagnostics for Ovarian Cancer Players by Revenue (2019-2024)
3.1.2 Global Therapies and Diagnostics for Ovarian Cancer Revenue Market Share by Players (2019-2024)
3.2 Global Therapies and Diagnostics for Ovarian Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Therapies and Diagnostics for Ovarian Cancer Revenue
3.4 Global Therapies and Diagnostics for Ovarian Cancer Market Concentration Ratio
3.4.1 Global Therapies and Diagnostics for Ovarian Cancer Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Therapies and Diagnostics for Ovarian Cancer Revenue in 2023
3.5 Therapies and Diagnostics for Ovarian Cancer Key Players Head office and Area Served
3.6 Key Players Therapies and Diagnostics for Ovarian Cancer Product Solution and Service
3.7 Date of Enter into Therapies and Diagnostics for Ovarian Cancer Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Therapies and Diagnostics for Ovarian Cancer Breakdown Data by Type
4.1 Global Therapies and Diagnostics for Ovarian Cancer Historic Market Size by Type (2019-2024)
4.2 Global Therapies and Diagnostics for Ovarian Cancer Forecasted Market Size by Type (2025-2030)
5 Therapies and Diagnostics for Ovarian Cancer Breakdown Data by Application
5.1 Global Therapies and Diagnostics for Ovarian Cancer Historic Market Size by Application (2019-2024)
5.2 Global Therapies and Diagnostics for Ovarian Cancer Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Therapies and Diagnostics for Ovarian Cancer Market Size (2019-2030)
6.2 North America Therapies and Diagnostics for Ovarian Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Therapies and Diagnostics for Ovarian Cancer Market Size by Country (2019-2024)
6.4 North America Therapies and Diagnostics for Ovarian Cancer Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Therapies and Diagnostics for Ovarian Cancer Market Size (2019-2030)
7.2 Europe Therapies and Diagnostics for Ovarian Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Therapies and Diagnostics for Ovarian Cancer Market Size by Country (2019-2024)
7.4 Europe Therapies and Diagnostics for Ovarian Cancer Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Therapies and Diagnostics for Ovarian Cancer Market Size (2019-2030)
8.2 Asia-Pacific Therapies and Diagnostics for Ovarian Cancer Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Therapies and Diagnostics for Ovarian Cancer Market Size by Region (2019-2024)
8.4 Asia-Pacific Therapies and Diagnostics for Ovarian Cancer Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Therapies and Diagnostics for Ovarian Cancer Market Size (2019-2030)
9.2 Latin America Therapies and Diagnostics for Ovarian Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Therapies and Diagnostics for Ovarian Cancer Market Size by Country (2019-2024)
9.4 Latin America Therapies and Diagnostics for Ovarian Cancer Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Therapies and Diagnostics for Ovarian Cancer Market Size (2019-2030)
10.2 Middle East & Africa Therapies and Diagnostics for Ovarian Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Therapies and Diagnostics for Ovarian Cancer Market Size by Country (2019-2024)
10.4 Middle East & Africa Therapies and Diagnostics for Ovarian Cancer Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Astra Zeneca
11.1.1 Astra Zeneca Company Detail
11.1.2 Astra Zeneca Business Overview
11.1.3 Astra Zeneca Therapies and Diagnostics for Ovarian Cancer Introduction
11.1.4 Astra Zeneca Revenue in Therapies and Diagnostics for Ovarian Cancer Business (2019-2024)
11.1.5 Astra Zeneca Recent Development
11.2 Clovis Oncology
11.2.1 Clovis Oncology Company Detail
11.2.2 Clovis Oncology Business Overview
11.2.3 Clovis Oncology Therapies and Diagnostics for Ovarian Cancer Introduction
11.2.4 Clovis Oncology Revenue in Therapies and Diagnostics for Ovarian Cancer Business (2019-2024)
11.2.5 Clovis Oncology Recent Development
11.3 Myriad
11.3.1 Myriad Company Detail
11.3.2 Myriad Business Overview
11.3.3 Myriad Therapies and Diagnostics for Ovarian Cancer Introduction
11.3.4 Myriad Revenue in Therapies and Diagnostics for Ovarian Cancer Business (2019-2024)
11.3.5 Myriad Recent Development
11.4 TESARO
11.4.1 TESARO Company Detail
11.4.2 TESARO Business Overview
11.4.3 TESARO Therapies and Diagnostics for Ovarian Cancer Introduction
11.4.4 TESARO Revenue in Therapies and Diagnostics for Ovarian Cancer Business (2019-2024)
11.4.5 TESARO Recent Development
11.5 AbbVie Inc
11.5.1 AbbVie Inc Company Detail
11.5.2 AbbVie Inc Business Overview
11.5.3 AbbVie Inc Therapies and Diagnostics for Ovarian Cancer Introduction
11.5.4 AbbVie Inc Revenue in Therapies and Diagnostics for Ovarian Cancer Business (2019-2024)
11.5.5 AbbVie Inc Recent Development
11.6 Celgene
11.6.1 Celgene Company Detail
11.6.2 Celgene Business Overview
11.6.3 Celgene Therapies and Diagnostics for Ovarian Cancer Introduction
11.6.4 Celgene Revenue in Therapies and Diagnostics for Ovarian Cancer Business (2019-2024)
11.6.5 Celgene Recent Development
11.7 Janssen Pharmaceuticals
11.7.1 Janssen Pharmaceuticals Company Detail
11.7.2 Janssen Pharmaceuticals Business Overview
11.7.3 Janssen Pharmaceuticals Therapies and Diagnostics for Ovarian Cancer Introduction
11.7.4 Janssen Pharmaceuticals Revenue in Therapies and Diagnostics for Ovarian Cancer Business (2019-2024)
11.7.5 Janssen Pharmaceuticals Recent Development
11.8 Merck
11.8.1 Merck Company Detail
11.8.2 Merck Business Overview
11.8.3 Merck Therapies and Diagnostics for Ovarian Cancer Introduction
11.8.4 Merck Revenue in Therapies and Diagnostics for Ovarian Cancer Business (2019-2024)
11.8.5 Merck Recent Development
11.9 Novartis AG
11.9.1 Novartis AG Company Detail
11.9.2 Novartis AG Business Overview
11.9.3 Novartis AG Therapies and Diagnostics for Ovarian Cancer Introduction
11.9.4 Novartis AG Revenue in Therapies and Diagnostics for Ovarian Cancer Business (2019-2024)
11.9.5 Novartis AG Recent Development
11.10 Quest Diagnostics Inc
11.10.1 Quest Diagnostics Inc Company Detail
11.10.2 Quest Diagnostics Inc Business Overview
11.10.3 Quest Diagnostics Inc Therapies and Diagnostics for Ovarian Cancer Introduction
11.10.4 Quest Diagnostics Inc Revenue in Therapies and Diagnostics for Ovarian Cancer Business (2019-2024)
11.10.5 Quest Diagnostics Inc Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
